XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Preferred Stock
Preferred Stock
Series D Convertible Preferred Stock
Common Stock
Common Stock
Series D Convertible Preferred Stock
Additional Paid-In Capital
Additional Paid-In Capital
Series D Convertible Preferred Stock
Additional Paid-In Capital
Series E Convertible Preferred Stock
Service Receivable
Accumulated Other Comprehensive Income/(Loss)
Accumulated Deficit
Accumulated Deficit
Series D Convertible Preferred Stock
Accumulated Deficit
Series E Convertible Preferred Stock
Balance, beginning (in shares) at Dec. 31, 2019   61,000   8,594,000                  
Balance, beginning at Dec. 31, 2019 $ 7,310 $ 0   $ 8   $ 217,172     $ (972) $ 0 $ (208,898)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 177         177              
Issuance of common stock upon exercise of warrants (in shares)       1,610,000                  
Issuance of common stock upon exercise of warrants 1,456         1,456              
Preferred stock dividend (6)                   (6)    
Release of clinical trial funding commitment 293               293        
Net loss (4,089)                   (4,089)    
Sale of common stock and warrants (in shares)       800,000                  
Sale of common stock and warrants 1,000         1,000              
Issuance of common stock upon vesting of restricted stock units (in shares)       7,000                  
Balance, ending (in shares) at Mar. 31, 2020   61,000   11,011,000                  
Balance, ending at Mar. 31, 2020 6,141 $ 0   $ 8   219,805     (679) 0 (212,993)    
Balance, beginning (in shares) at Dec. 31, 2019   61,000   8,594,000                  
Balance, beginning at Dec. 31, 2019 7,310 $ 0   $ 8   217,172     (972) 0 (208,898)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss (12,710)                        
Balance, ending (in shares) at Sep. 30, 2020   927,000   26,286,000                  
Balance, ending at Sep. 30, 2020 33,521 $ 1   $ 10   260,807     (2,404) 0 (224,893)    
Balance, beginning (in shares) at Mar. 31, 2020   61,000   11,011,000                  
Balance, beginning at Mar. 31, 2020 6,141 $ 0   $ 8   219,805     (679) 0 (212,993)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 282         282              
Issuance of common stock upon exercise of warrants (in shares)       3,473,000                  
Issuance of common stock upon exercise of warrants 4,605         4,605              
Preferred stock dividend (6)                   (6)    
Release of clinical trial funding commitment 213               213        
Net loss (4,124)                   (4,124)    
Issuance of common stock upon vesting of restricted stock units (in shares)       2,000                  
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares)   155,000   603,000                  
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (8)         2,292     (2,300)        
Deemed dividend             $ 602 $ 2,665       $ (602) $ (2,665)
Sale of stock, number of shares issued (in shares) [1]   866,000   4,689,000                  
Proceeds from sale of stock [1] 17,279 $ 1   $ 1   17,277              
Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares)     (155,000)   1,547,000                
Balance, ending (in shares) at Jun. 30, 2020   927,000   21,325,000                  
Balance, ending at Jun. 30, 2020 24,382 $ 1   $ 9   247,528     (2,766) 0 (220,390)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 362         362              
Issuance of common stock upon exercise of warrants (in shares)       4,957,000                  
Issuance of common stock upon exercise of warrants 12,911     $ 1   12,910              
Preferred stock dividend (6)                   (6)    
Release of clinical trial funding commitment 362               362        
Net loss (4,497)                   (4,497)    
Issuance of common stock upon vesting of restricted stock units (in shares)       1,000                  
Issuance of common stock upon exercise of stock options (in shares)       3,000                  
Issuance of common stock upon exercise of stock options 7         7              
Balance, ending (in shares) at Sep. 30, 2020   927,000   26,286,000                  
Balance, ending at Sep. 30, 2020 33,521 $ 1   $ 10   260,807     (2,404) 0 (224,893)    
Balance, beginning (in shares) at Dec. 31, 2020   716,000   36,781,000                  
Balance, beginning at Dec. 31, 2020 128,158 $ 1   $ 4   361,819     (2,171) 0 (231,495)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 268         268              
Issuance of common stock upon exercise of warrants (in shares)       771,000                  
Issuance of common stock upon exercise of warrants 1,263         1,263              
Other comprehensive gain (loss) (67)                 (67)      
Preferred stock dividend (6)                   (6)    
Release of clinical trial funding commitment 380               380        
Net loss (5,179)                   (5,179)    
Balance, ending (in shares) at Mar. 31, 2021   716,000   37,552,000                  
Balance, ending at Mar. 31, 2021 124,817 $ 1   $ 4   363,350     (1,791) (67) (236,680)    
Balance, beginning (in shares) at Dec. 31, 2020   716,000   36,781,000                  
Balance, beginning at Dec. 31, 2020 128,158 $ 1   $ 4   361,819     (2,171) 0 (231,495)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss (18,849)                        
Balance, ending (in shares) at Sep. 30, 2021   716,000   39,552,000                  
Balance, ending at Sep. 30, 2021 133,544 $ 1   $ 4   384,551     (666) 16 (250,362)    
Balance, beginning (in shares) at Mar. 31, 2021   716,000   37,552,000                  
Balance, beginning at Mar. 31, 2021 124,817 $ 1   $ 4   363,350     (1,791) (67) (236,680)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 1,036         1,036              
Other comprehensive gain (loss) 57                 57      
Preferred stock dividend (6)                   (6)    
Release of clinical trial funding commitment 546               546        
Net loss (6,757)                   (6,757)    
Sale of common stock, net of expenses (in shares) [2]       2,000,000                  
Sale of common stock, net of expenses [2] 19,225         19,225              
Balance, ending (in shares) at Jun. 30, 2021   716,000   39,552,000                  
Balance, ending at Jun. 30, 2021 138,918 $ 1   $ 4   383,611     (1,245) (10) (243,443)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 940         940              
Other comprehensive gain (loss) 26                 26      
Preferred stock dividend (6)                   (6)    
Release of clinical trial funding commitment 579               579        
Net loss (6,913)                   (6,913)    
Balance, ending (in shares) at Sep. 30, 2021   716,000   39,552,000                  
Balance, ending at Sep. 30, 2021 $ 133,544 $ 1   $ 4   $ 384,551     $ (666) $ 16 $ (250,362)    
[1] Net of expenses of $0.6 million, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $0.4 million.
[2] Net of expenses of $0.8 million.